文献速递类风湿关节炎脊柱关节炎

COVID-19大流行对炎症性关节病患者及一般人群发病率与死亡率的影响:瑞典全国队列研究

Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study.
PubMed 文献 · Ann Rheum Dis · 2021-02-23

该瑞典全国多登记链接队列研究纳入类风湿关节炎(RA,n=53 455)和其他炎症性关节病(IJD,n=57 112)成人患者及个体匹配的一般人群参照,比较2015-2020年3-9月年度全因死亡率,并评估2020年3-9月COVID-19住院、重症监护入住和死亡的风险。结果显示IJD患者COVID-19重症结局风险增高,但绝对风险和超额风险低,风险增加程度与一般人群大致成比例,且可由合并症解释;抗风湿药物未与严重COVID-19结局风险增加相关。

要点

  • IJD患者COVID-19住院、ICU入住和死亡风险较参照人群增高,但绝对风险低。
  • 2020年RA和其他IJD全因死亡率高于2015-2019年,但相对一般人群的风险比与既往相似。
  • 抗风湿药物未显示与严重COVID-19结局风险增加相关,部分药物精确性有限。

核心结论

  • IJD患者COVID-19严重结局风险增高,但绝对风险和超额风险低。
  • 风险增加程度与一般人群大致成比例,且可由合并症解释。
  • 抗风湿药物可能除外,对上述风险无重大影响。

研究设计与样本

  • 瑞典全国多登记链接队列研究,纳入RA患者n=53 455、其他IJD患者n=57 112及个体匹配的一般人群参照。
  • 比较2015-2020年3-9月年度全因死亡率,并使用Cox回归评估2020年3-9月COVID-19住院、ICU入住和死亡的绝对与相对风险。

主要发现

  • 2020年3-9月RA和其他IJD的绝对全因死亡率高于2015-2019年,但相对一般人群的风险比(约2和1.5)与2015-2019年相似。
  • IJD患者COVID-19住院率为0.5%(参照人群0.3%),ICU入住率为0.04%(参照0.03%),死亡率为0.10%(参照0.07%)。
  • 抗风湿药物未与严重COVID-19结局风险增加相关,但某些药物的精确性有限。

关键数值与推荐

  • RA患者n=53 455(2020年3月),其他IJD(脊柱关节炎、银屑病关节炎和幼年特发性关节炎)n=57 112。
  • COVID-19住院率:IJD患者0.5% vs 参照人群0.3%。
  • COVID-19 ICU入住率:IJD患者0.04% vs 参照人群0.03%。
  • COVID-19死亡率:IJD患者0.10% vs 参照人群0.07%。
  • 相对一般人群的全因死亡风险比:RA约2,其他IJD约1.5,2020年与2015-2019年相似。

临床怎么用

  • IJD患者COVID-19严重结局的绝对风险低,临床应关注合并症管理而非过度担忧抗风湿药物。
  • 抗风湿药物未显示增加严重COVID-19结局风险,可继续按指南使用。

局限性

  • 某些抗风湿药物的精确性有限。
  • 研究为观察性设计,可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To estimate absolute and relative risks for all-cause mortality and for severe COVID-19 in inflammatory joint diseases (IJDs) and with antirheumatic therapies. METHODS: Through Swedish nationwide multiregister linkages, we selected all adult patients with rheumatoid arthritis (RA, n=53 455 in March 2020), other IJDs (here: spondyloarthropathies, psoriatic arthritis and juvenile idiopathic arthritis, n=57 112), their antirheumatic drug use, and individually matched population referents. We compared annual all-cause mortality March-September 2015 through 2020 within and across cohorts, and assessed absolute and relative risks for hospitalisation, admission to intensive care and death due to COVID-19 March-September 2020, using Cox regression. RESULTS: During March-September 2020, the absolute all-cause mortality in RA and in other IJDs was higher than 2015-2019, but relative risks versus the general population (around 2 and 1.5) remained similar during 2020 compared with 2015-2019. Among patients with IJD, the risks of hospitalisation (0.5% vs 0.3% in their population referents), admission to intensive care (0.04% vs 0.03%) and death (0.10% vs 0.07%) due to COVID-19 were low. Antirheumatic drugs were not associated with increased risk of serious COVID-19 outcomes, although for certain drugs, precision was limited. CONCLUSIONS: Risks of severe COVID-19-related outcomes were increased among patients with IJDs, but risk increases were also seen for non-COVID-19 morbidity. Overall absolute and excess risks are low and the level of risk increases are largely proportionate to those in the general population, and explained by comorbidities. With possible exceptions, antirheumatic drugs do not have a major impact on these risks.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Bower H, Frisell T, Di Giuseppe D, et al. Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Ann Rheum Dis. 2021. PMID: 33622688. doi:10.1136/annrheumdis-2021-219845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。